<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Yichang Zhao – Academic Homepage</title>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;600;700&display=swap" rel="stylesheet" />
  <style>
    body {
      margin: 0;
      font-family: "Inter", sans-serif;
      background: #f6f8fc;
      color: #222;
      line-height: 1.7;
    }
    header {
      background: #0d3b66;
      color: white;
      padding: 60px 20px;
      text-align: center;
    }
    header h1 {
      margin: 0;
      font-size: 3rem;
      font-weight: 700;
    }
    header p {
      margin-top: 10px;
      font-size: 1.2rem;
      opacity: 0.9;
    }
    .container {
      max-width: 1000px;
      margin: 40px auto;
      background: white;
      padding: 40px;
      border-radius: 16px;
      box-shadow: 0 8px 24px rgba(0,0,0,0.08);
    }
    h2 {
      margin-top: 40px;
      color: #0d3b66;
      font-weight: 700;
      border-left: 6px solid #0d3b66;
      padding-left: 12px;
    }
    ul { padding-left: 25px; }
    li { margin-bottom: 8px; }
    a {
      color: #0d3b66;
      text-decoration: none;
      font-weight: 600;
    }
    a:hover { text-decoration: underline; }
    .footer {
      margin-top: 50px;
      text-align: center;
      padding: 30px;
      font-size: 0.9rem;
      color: #555;
    }
  </style>
</head>

<body>
  <header>
    <h1>Yichang Zhao</h1>
    <p>PhD Candidate · Clinical Pharmacy · Central South University</p>
  </header>

  <div class="container">

    <!-- About Me -->
    <h2>About</h2>
    <p>
      Email: <a href="mailto:zhaoyichang@csu.edu.cn">zhaoyichang@csu.edu.cn</a><br/>
      ORCID: <a href="https://orcid.org/0000-0002-9651-4457">0000-0002-9651-4457</a>
    </p>
    <p>
      Research activities focus on antimicrobial pharmacology, infectious disease epidemiology,
      and clinical pharmacokinetics. Current work emphasizes optimization of antimicrobial therapy,
      characterization of PK/PD variability, and identification of clinical and environmental 
      determinants of antimicrobial resistance.
    </p>
    <p>
      Quantitative methodologies include meta-analysis, population pharmacokinetic (PopPK) modeling,
      real-world evidence analysis, and causal inference to support individualized dosing and 
      evidence-based antimicrobial stewardship.
    </p>
    <p>
      Published research includes multiple first-author articles in international peer-reviewed
      journals across pharmacology, infectious diseases, and environmental health.
    </p>

    <!-- Research Interests -->
    <h2>Research Interests</h2>
    <ul>
      <li>Antimicrobial pharmacology</li>
      <li>Antimicrobial resistance epidemiology</li>
      <li>Population PK/PD modeling</li>
      <li>Clinical pharmacokinetics & TDM</li>
      <li>Meta-analysis & real-world evidence</li>
      <li>Causal inference in clinical pharmaco-epidemiology</li>
    </ul>

    <!-- Employment -->
    <h2>Employment</h2>
    <ul>
      <li><strong>Second Xiangya Hospital, Central South University</strong> (2017.07–2019.07) – Administrative Secretary, GCP Office & Medical Ethics Committee</li>
      <li><strong>First Affiliated Hospital of Hunan University of Medicine</strong> (2014.07–2015.07) – Clinical Pharmacist</li>
    </ul>

    <!-- Education -->
    <h2>Education</h2>
    <ul>
      <li><strong>Ph.D., Clinical Pharmacy</strong>, Central South University (2022–2026)</li>
      <li><strong>Master, Clinical Pharmacy</strong>, Central South University (2019–2022)</li>
      <li><strong>Bachelor, Pharmacy</strong>, Xiangya School of Medicine, Central South University (2010–2014)</li>
    </ul>

    <!-- Distinctions -->
    <h2>Distinctions & Honors</h2>
    <ul>
      <li>National Doctoral Scholarship – Ministry of Education (2022, 2024, 2025)</li>
      <li>Selected Young Scientist – 72nd Lindau Nobel Laureate Meeting (NSFC–DFG Sino-German Center)</li>
      <li>Person of the Year – Central South University (2023)</li>
      <li>CSU Innovation Award · President’s Scholarship (2023)</li>
    </ul>

    <!-- Funding -->
    <h2>Funding</h2>
    <ul>
      <li><strong>NIHAYSZX2502</strong> – IoT-/GIS-based CR-GNB infection warning system · National Health Commission of China</li>
      <li><strong>202113012480</strong> – Voriconazole dosing in hepatic dysfunction · Health Commission of Hunan Province</li>
    </ul>

    <!-- Publications -->
    <h2>Publications (Selected)</h2>
    <p>Full list available on <a href="https://scholar.google.com/citations?user=ZrNKcgIAAAAJ">Google Scholar</a>.</p>

    <ul>
      <!-- 30 publications condensed -->
      <li>BMC Medical Education (2025) – PGGCES evaluation scale · DOI: 10.1186/s12909-025-07859-4</li>
      <li>Cardiovascular Diabetology (2025) – TG–glucose index & frailty index · DOI: 10.1186/s12933-025-02880-9</li>
      <li>Environmental Sciences Europe (2025) – Gram-negative mortality pathway · DOI: 10.1186/s12302-025-01111-y</li>
      <li>Frontiers in Pharmacology (2025) – MRSA co-infection & sepsis mortality · DOI: 10.3389/fphar.2025.1534107</li>
      <li>Scientific Reports (2025) – PBPK & CYP3A4/5–CYP2C19 interactions · DOI: 10.1038/s41598-025-91356-7</li>
      <li>Environmental Sciences Europe (2025) – MRSA environmental determinants · DOI: 10.1186/s12302-025-01064-2</li>
      <li>Frontiers in Pharmacology (2024) – Tacrolimus–voriconazole PopPK · DOI: 10.3389/fphar.2024.1439232</li>
      <li>IJAA (2024) – Polymyxin B meta-analysis · DOI: 10.1016/j.ijantimicag.2024.107262</li>
      <li>Environmental Research (2024) – E. coli–climate analysis · DOI: 10.1016/j.envres.2023.117995</li>
      <li>Frontiers in Pharmacology (2023) – Voriconazole liver dysfunction PK · DOI: 10.3389/fphar.2023.1323755</li>
      <li>Phytomedicine (2023) – Glycyrrhizic acid NMA · DOI: 10.1016/j.phymed.2023.154883</li>
      <li>Pharmaceutics (2022) – Tacrolimus–voriconazole interaction · DOI: 10.3390/pharmaceutics14122739</li>
      <li>Antibiotics (2022) – C/MIC > 4 indicator · DOI: 10.3390/antibiotics11050670</li>
      <li>Infectious Diseases and Therapy (2022) – Meropenem prolonged infusion · DOI: 10.1007/s40121-021-00551-2</li>
      <li>British Journal of Clinical Pharmacology (2021) – Voriconazole PK in liver dysfunction · DOI: 10.1111/bcp.14578</li>
      <li>Clinical and Translational Science (2021) – Voriconazole trough predictors · DOI: 10.1111/cts.12932</li>
    </ul>

    <!-- Links -->
    <h2>Links</h2>
    <ul>
      <li><a href="https://orcid.org/0000-0002-9651-4457">ORCID</a></li>
      <li><a href="https://scholar.google.com/citations?user=ZrNKcgIAAAAJ">Google Scholar</a></li>
      <li><a href="https://www.researchgate.net/profile/Yichang-Zhao">ResearchGate</a></li>
    </ul>

  </div>

  <div class="footer">
    © 2025 Yichang Zhao · Academic Homepage
  </div>
</body>
</html>

